Einführung

A veterinary catheter patent infringement lawsuit filed in the Eastern District of Kentucky concluded with a negotiated dismissal with prejudice, offering instructive lessons for IP professionals operating in the medical device and veterinary equipment space. In *Garrouzoo, Inc. v. Mila International, Inc.* (Case No. 2:21-cv-00001), plaintiff Garrouzoo, Inc. alleged infringement of two U.S. patents covering catheter securement technology, targeting Mila International’s line of CathCollar veterinary catheter securement devices across multiple size variants. The case, filed January 4, 2021, and closed April 3, 2024, resolved through a mutual settlement agreement — with all claims and counterclaims dismissed with prejudice and each party bearing its own costs and attorney fees.

For patent attorneys, in-house IP counsel, and R&D decision-makers in the veterinary medical device sector, this case underscores the strategic interplay between patent assertion, product competition, and negotiated resolution — particularly when commercially significant product lines are at stake.

Fallübersicht

Die Parteien

Die streitigen Patente

Two U.S. patents formed the foundation of Garrouzoo’s infringement claims. Both patents relate to devices used to stabilize intravenous or similar catheters in veterinary patients — a niche but commercially active segment within the broader animal health product market. Readers can review both patents directly via the USPTO Patent Full-Text Database.

• • U.S. Patent No. 8,757,100 — covering catheter securement device technology
• • U.S. Patent No. 8,539,912 — covering related catheter collar or securement apparatus claims

Beschuldigte Produkte

Mila International’s **CathCollar product line** — spanning ten distinct size and series variants (CCP-L, CCP-M, CCP-S, CCP-XL, CCP-XS, CCS-L, CCS-M, CCS-S, CCS-XL, and CCS-XS) — formed the commercial core of the infringement allegations. The breadth of accused products across multiple sizes and configurations suggests Garrouzoo pursued a comprehensive assertion strategy targeting MILA’s full commercial offering in this category.

Zeitplan des Rechtsstreits und Verfahrensgeschichte

Garrouzoo, Inc. v. Mila International, Inc. was filed on January 4, 2021, in the U.S. District Court for the Eastern District of Kentucky, presided over by Chief Judge David L. Bunning. The Eastern District of Kentucky, while not a traditionally high-volume patent litigation venue, provides a structured docket environment that can benefit plaintiffs seeking focused judicial attention on technically complex matters.

The case remained active at the first-instance (district court) trial level throughout its duration, closing on April 3, 2024 — a litigation span of approximately three years and three months. This extended timeline is characteristic of patent infringement cases involving claim construction proceedings, potential expert discovery, and parallel settlement negotiations.

The final resolution came through a Rule 41(a) voluntary dismissal with prejudice, filed jointly by both parties pursuant to their settlement agreement. No PTAB inter partes review (IPR) filings or appellate proceedings are reflected in the available case data. The dismissal structure — with each party bearing its own costs — is a common indicator of a confidential, negotiated resolution rather than a contested court ruling on the merits.

Case records are accessible via PACER using Case No. 2:21-cv-00001.

Das Urteil und die rechtliche Analyse

Ergebnis

The case concluded with all claims and counterclaims dismissed with prejudice pursuant to a settlement agreement between the parties, as stipulated under Federal Rule of Civil Procedure 41(a). No damages figure was publicly disclosed, and no injunctive relief order was entered as part of the public record. The mutual cost-bearing arrangement suggests a negotiated compromise rather than a clear prevailing party.

Urteilsursachenanalyse

The operative cause of action was patent infringement, with Garrouzoo asserting that MILA’s CathCollar devices — across all commercially available size variants — practiced claims within U.S. Patents 8,757,100 and 8,539,912. Because the case resolved through settlement before any publicly documented claim construction order or summary judgment ruling, the specific legal theories tested — whether literal infringement, doctrine of equivalents, or validity challenges — remain shielded by the terms of the private agreement.

The assertion of counterclaims by MILA, referenced in the joint dismissal language, signals that the defendant mounted an affirmative defense posture — potentially including invalidity contentions, non-infringement arguments, or both. The presence of counterclaims is strategically significant: it suggests MILA did not pursue early dismissal on procedural grounds alone but engaged substantively on the merits, which may have contributed to the parties’ eventual willingness to negotiate.

Rechtliche Bedeutung

Because the case was resolved without a dispositive ruling, it carries limited direct precedential value for claim construction or infringement doctrine in the veterinary catheter securement technology space. However, the case is instructive on several practical dimensions:

• Venue selection: The Eastern District of Kentucky is a deliberate choice for IP litigants seeking a less congested docket and experienced district court judges.
• Multi-product assertion: Garrouzoo’s strategy of naming the entire CathCollar product family across size variants signals an intent to maximize commercial leverage and settlement value.
• Counterclaim dynamics: MILA’s filing of counterclaims reflects a standard defensive posture that raises the stakes for patent holders, who must then defend their patents’ validity in addition to proving infringement.